Algernon Pharmaceuticals Inc.


Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs. Algernon has active research programs for idiopathic pulmonary fibrosis ("IPF") with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke. Two of Algernon's lead drugs are based on drug repurposing and the third compound is a naturally occurring psychedelic drug. Drug repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life. Our program specifically investigates compounds that have never been approved in the U.S. or Europe. We protect our lead compounds with method of use, dosing, and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient, and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.

streetwise book logoStreetwise - Algernon Pharmaceuticals Inc. Ownership Overview*

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA)

*Share Structure as of 12/27/2023